GeneDx Holdings Corp. (WGS) stock
WGSNasdaqServices-Health ServicesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 6/3058% above fair value
$51.96+4.67 (+9.88%)
Close on Nov 18, 2026Market cap $1.55BP/E –Yield –
GeneDx operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
GeneDx's operating cash flow for the twelve months ending Jun 30, 2026 was -$48.71M, down 474.0% year over year. For fiscal 2025 it was $33.28M. The highest annual figure on record is $33.28M in fiscal 2025.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $33.28M | – |
| FY2024 | Dec 31, 2024 | -$28.50M | – |
| FY2023 | Dec 31, 2023 | -$180.15M | – |
| FY2022 | Dec 31, 2022 | -$319.16M | – |
| FY2021 | Dec 31, 2021 | -$190.43M | – |
| FY2020 | Dec 31, 2020 | -$93.13M | – |
| FY2019 | Dec 31, 2019 | -$18.73M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$28.98M | -378.1% |
| Q1 FY2026 | Mar 31, 2026 | -$32.41M | -418.3% |
| Q4 FY2025 | Dec 31, 2025 | -$3.09M | – |
| Q3 FY2025 | Sep 30, 2025 | $15.77M | – |
| Q2 FY2025 | Jun 30, 2025 | $10.42M | – |
| Q1 FY2025 | Mar 31, 2025 | $10.18M | – |
| Q4 FY2024 | Dec 31, 2024 | -$3.18M | – |
| Q3 FY2024 | Sep 30, 2024 | -$4.40M | – |
| Q2 FY2024 | Jun 30, 2024 | -$4.51M | – |
| Q1 FY2024 | Mar 31, 2024 | -$16.41M | – |
| Q4 FY2023 | Dec 31, 2023 | -$29.86M | – |
| Q3 FY2023 | Sep 30, 2023 | -$41.23M | – |
| Q2 FY2023 | Jun 30, 2023 | -$53.50M | – |
| Q1 FY2023 | Mar 31, 2023 | -$55.56M | – |
| Q4 FY2022 | Dec 31, 2022 | -$64.65M | – |
| Q3 FY2022 | Sep 30, 2022 | -$88.36M | – |
| Q2 FY2022 | Jun 30, 2022 | -$84.65M | – |
| Q1 FY2022 | Mar 31, 2022 | -$81.49M | – |
| Q4 FY2021 | Dec 31, 2021 | -$51.99M | – |
| Q3 FY2021 | Sep 30, 2021 | -$70.94M | – |
| Q2 FY2021 | Jun 30, 2021 | -$25.30M | – |
| Q1 FY2021 | Mar 31, 2021 | -$42.21M | – |
| Q4 FY2020 | Dec 31, 2020 | -$18.33M | – |
| Q3 FY2020 | Sep 30, 2020 | -$365.81K | – |
See a number that looks wrong?